{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:19:18Z","timestamp":1793949558249,"version":"4.8.0"},"reference-count":258,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIHR Oxford Health Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Mental Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel drugs approved for diabetes and obesity. They are acknowledged as a major scientific breakthrough. In addition to their metabolic effects, these medications act on other bodily systems involved in the physiopathology of various neurological and psychiatric disorders. Several stakeholders are calling for more research to investigate the repurposing potential of GLP-1RAs in cognitive and mental disorders, while others advocate for a better assessment of their safety profile from a neuropsychiatric perspective. In this Analysis, we searched for relevant literature on the effects of GLP-1RAs across a range of illnesses, gathering and describing the available pre-clinical and mechanistic (278 studies) and clinical (96 studies) evidence for cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, eating disorders, and others. By leveraging translational insights from these data, we consider potential implications for clinical practice and propose avenues for further research.<\/jats:p>","DOI":"10.1038\/s44220-025-00390-x","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:03:12Z","timestamp":1739422992000},"page":"354-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-8696","authenticated-orcid":false,"given":"Riccardo","family":"De Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-8300","authenticated-orcid":false,"given":"Ana","family":"Ghenciulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliwia","family":"Dziwisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-952X","authenticated-orcid":false,"given":"Maxime","family":"Taquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda I.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Koychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-5103","authenticated-orcid":false,"given":"Rachel","family":"Upthegrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-2566","authenticated-orcid":false,"given":"Robert","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-6138","authenticated-orcid":false,"given":"Philip J.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-8335","authenticated-orcid":false,"given":"Catherine J.","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"390_CR1","unstructured":"Collins, L. & Costello, R. A. Glucagon-Like Peptide-1 Receptor Agonists (StatPearls Publishing, 2024)."},{"key":"390_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bph.15508","volume":"179","author":"C H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher, C. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br. J. Pharmacol. 179, 695\u2013714 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130 (2019).","journal-title":"Mol. Metab."},{"key":"390_CR4","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2147\/DMSO.S375559","volume":"15","author":"M Dong","year":"2022","unstructured":"Dong, M., Wen, S. & Zhou, L. The relationship between the blood\u2013brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab. Syndr. Obes. 15, 2583\u20132597 (2022).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"390_CR5","doi-asserted-by":"publisher","unstructured":"Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.133429 (2020).","DOI":"10.1172\/jci.insight.133429"},{"key":"390_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bph.15638","volume":"179","author":"S Trapp","year":"2022","unstructured":"Trapp, S. & Brierley, D. I. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br. J. Pharmacol. 179, 557\u2013570 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"390_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","volume":"3","author":"DI Brierley","year":"2021","unstructured":"Brierley, D. I. et al. Central and peripheral GLP-1 systems independently suppress eating. Nat. Metab. 3, 258\u2013273 (2021).","journal-title":"Nat. Metab."},{"key":"390_CR8","unstructured":"Fernando, K. Oral GLP-1 agonists could be game changers for obesity. Medscape https:\/\/www.medscape.com\/viewarticle\/993984?form=fpf (2023)."},{"key":"390_CR9","unstructured":"Yeo, G. Hollywood\u2019s favourite \u2018skinny jab\u2019 is coming to the NHS. And it could be a weight-loss game-changer. BBC Science Focus https:\/\/www.sciencefocus.com\/comment\/semaglutide (2023)."},{"key":"390_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41586-022-04505-7","volume":"613","author":"M Prillaman","year":"2023","unstructured":"Prillaman, M. The \u2018breakthrough\u2019 obesity drugs that have stunned researchers. Nature 613, 16\u201318 (2023).","journal-title":"Nature"},{"key":"390_CR11","unstructured":"GLP-1 Receptor Agonist Market\u2014by Drug Class, by Route of Administration, by Application, by Distribution, Global Forecast, 2024\u20132032 (GMI, 2023); https:\/\/www.gminsights.com\/industry-analysis\/glp-1-receptor-agonist-market"},{"key":"390_CR12","unstructured":"Boaz, J. Semaglutide is causing a social media frenzy. So what is it? ABC News https:\/\/www.abc.net.au\/news\/2022-12-17\/semaglutide-shortage-supply-australia-obesity-diabetes\/101708510 (2022)."},{"key":"390_CR13","unstructured":"Current and Resolved Drug Shortages and Discontinuations Reported to FDA (US FDA, 2023); https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/"},{"key":"390_CR14","unstructured":"European Medicines Agency. Shortage of Ozempic (semaglutide). EMA https:\/\/www.ema.europa.eu\/en\/medicines\/human\/shortages\/ozempic (2023)."},{"key":"390_CR15","first-page":"8","volume":"47","author":"B Brown","year":"2017","unstructured":"Brown, B., Alphs, L., Turkoz, I. & Yue, Y. Baseline demographics and characteristics from a paliperidone palmitate study in subjects with recent-onset schizophrenia or schizophreniform disorder. Psychopharmacol. Bull. 47, 8\u201316 (2017).","journal-title":"Psychopharmacol. Bull."},{"key":"390_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/cd23-0023","volume":"41","author":"HP Whitley","year":"2023","unstructured":"Whitley, H. P., Trujillo, J. M. & Neumiller, J. J. Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages. Clin. Diabetes 41, 467\u2013473 (2023).","journal-title":"Clin. Diabetes"},{"key":"390_CR17","doi-asserted-by":"publisher","unstructured":"Shi, Q. et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ https:\/\/doi.org\/10.1136\/bmj-2022-074068 (2023).","DOI":"10.1136\/bmj-2022-074068"},{"key":"390_CR18","doi-asserted-by":"publisher","unstructured":"Alkhezi, O. S. et al. Comparative effectiveness of glucagon\u2010like peptide\u20101 receptor agonists for the management of obesity in adults without diabetes: a network meta\u2010analysis of randomized clinical trials. Obes. Rev. https:\/\/doi.org\/10.1111\/obr.13543 (2023).","DOI":"10.1111\/obr.13543"},{"key":"390_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2352-4642(19)30236-6","volume":"3","author":"F Bacha","year":"2019","unstructured":"Bacha, F. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children. Lancet Child Adolesc. Health 3, 595\u2013597 (2019).","journal-title":"Lancet Child Adolesc. Health"},{"key":"390_CR20","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber, D. et al. Once-weekly semaglutide in adolescents with obesity. N. Engl. J. Med. 387, 2245\u20132257 (2022).","journal-title":"N. Engl. J. Med."},{"key":"390_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/d41586-023-02528-2","volume":"620","author":"M Lenharo","year":"2023","unstructured":"Lenharo, M. Anti-obesity drug also protects against heart disease\u2014what happens next? Nature 620, 480 (2023).","journal-title":"Nature"},{"key":"390_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841\u2013851 (2019).","journal-title":"N. Engl. J. Med."},{"key":"390_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/dom.14487","volume":"23","author":"EK Bain","year":"2021","unstructured":"Bain, E. K. & Bain, S. C. Recent developments in GLP-1RA therapy: a review of the latest evidence of efficacy and safety and differences within the class. Diabetes Obes. Metab. 23, 30\u201339 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR24","doi-asserted-by":"publisher","first-page":"e068652","DOI":"10.1136\/bmjopen-2022-068652","volume":"13","author":"MR Sass","year":"2023","unstructured":"Sass, M. R. et al. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open 13, e068652 (2023).","journal-title":"BMJ Open"},{"key":"390_CR25","doi-asserted-by":"publisher","unstructured":"Battini, V. et al. The potential antidepressant effect of antidiabetic agents: new insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1128387 (2023).","DOI":"10.3389\/fphar.2023.1128387"},{"key":"390_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jpsychires.2023.05.041","volume":"164","author":"DH Cooper","year":"2023","unstructured":"Cooper, D. H. et al. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review. J. Psychiatr. Res. 164, 80\u201389 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"390_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s43440-021-00274-8","volume":"73","author":"J Detka","year":"2021","unstructured":"Detka, J. & G\u0142ombik, K. Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacol. Rep. 73, 1020\u20131032 (2021).","journal-title":"Pharmacol. Rep."},{"key":"390_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","volume":"30","author":"J Flintoff","year":"2021","unstructured":"Flintoff, J., Kesby, J. P., Siskind, D. & Burne, T. H. Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential. Expert Opin. Investig. Drugs 30, 877\u2013891 (2021).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"390_CR29","unstructured":"Kunzmann, K. Roger S. McIntyre, MD: GLP-1 agonists for psychiatry? HCP Live https:\/\/www.hcplive.com\/view\/roger-mcintyre-md-glp-1-agonists-for-psychiatry (2024)."},{"key":"390_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.neuropharm.2018.01.048","volume":"136","author":"RB Mansur","year":"2018","unstructured":"Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E. & McIntyre, R. S. Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology 136, 335\u2013342 (2018).","journal-title":"Neuropharmacology"},{"key":"390_CR31","doi-asserted-by":"publisher","first-page":"11301","DOI":"10.3390\/ijms241411301","volume":"24","author":"MC Pelle","year":"2023","unstructured":"Pelle, M. C., Zaffina, I., Giofr\u00e8, F., Pujia, R. & Arturi, F. Potential role of glucagon-like peptide-1 receptor agonists in the treatment of cognitive decline and dementia in diabetes mellitus. Int. J. Mol. Sci. 24, 11301 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"390_CR32","doi-asserted-by":"publisher","unstructured":"Tsai, W.-H. et al. Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: a nationwide, population-based cohort study. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.765446 (2022).","DOI":"10.3389\/fphar.2022.765446"},{"key":"390_CR33","doi-asserted-by":"publisher","unstructured":"Kong, F. et al. Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: a systematic review and meta-analysis of preclinical studies. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1205207 (2023).","DOI":"10.3389\/fphar.2023.1205207"},{"key":"390_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell, J., Blunt, E. & Edison, P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease. Mol. Psychiatry 28, 217\u2013229 (2023).","journal-title":"Mol. Psychiatry"},{"key":"390_CR35","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 19, 758\u2013766 (2020).","journal-title":"Lancet Neurol."},{"key":"390_CR36","doi-asserted-by":"publisher","unstructured":"Reich, N. & H\u00f6lscher, C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front. Neurosci. https:\/\/doi.org\/10.3389\/fnins.2022.970925 (2022).","DOI":"10.3389\/fnins.2022.970925"},{"key":"390_CR37","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","volume":"33","author":"D Erbil","year":"2019","unstructured":"Erbil, D. et al. GLP-1\u2019s role in neuroprotection: a systematic review. Brain Inj. 33, 734\u2013819 (2019).","journal-title":"Brain Inj."},{"key":"390_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1047883","volume":"13","author":"S Luan","year":"2022","unstructured":"Luan, S., Cheng, W., Wang, C., Gong, J. & Zhou, J. Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front. Endocrinol. 13, 1047883 (2022).","journal-title":"Front. Endocrinol."},{"key":"390_CR39","volume":"8","author":"CH Norgaard","year":"2022","unstructured":"Norgaard, C. H. et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement. 8, e12268 (2022).","journal-title":"Alzheimers Dement."},{"key":"390_CR40","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/jgs.18306","volume":"71","author":"H Tang","year":"2023","unstructured":"Tang, H. et al. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J. Am. Geriatr. Soc. 71, 2096\u20132106 (2023).","journal-title":"J. Am. Geriatr. Soc."},{"key":"390_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3673","volume":"39","author":"S Tian","year":"2023","unstructured":"Tian, S. et al. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab. Res. Rev. 39, e3673 (2023).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"390_CR42","doi-asserted-by":"crossref","unstructured":"Cheng, H. et al. Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study. Diabetes Care 45, 1201\u20131210 (2022).","DOI":"10.2337\/dc21-2064"},{"key":"390_CR43","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 19, 582\u2013590 (2020).","journal-title":"Lancet Neurol."},{"key":"390_CR44","unstructured":"Wang, Q., Wang, D., Cheng, A., Sun, F. Y. & Li, Z. J. Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment. Int. J. Clin. Exp. Med. 13, 1219\u20131227 (2020)."},{"key":"390_CR45","doi-asserted-by":"crossref","unstructured":"Li, Q. et al. Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway. J. Am. Heart Assoc. 10, e020734 (2021).","DOI":"10.1161\/JAHA.120.020734"},{"key":"390_CR46","doi-asserted-by":"crossref","unstructured":"Zhang, Z. et al. Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies. Diabetes Care 42, 1274\u20131283 (2019).","DOI":"10.2337\/dc18-2584"},{"key":"390_CR47","doi-asserted-by":"crossref","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","DOI":"10.1056\/NEJMoa1607141"},{"key":"390_CR48","doi-asserted-by":"crossref","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","DOI":"10.1056\/NEJMoa1603827"},{"key":"390_CR49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/JAD-180808","volume":"66","author":"J Bohlken","year":"2018","unstructured":"Bohlken, J., Jacob, L. & Kostev, K. Association between the use of antihyperglycemic drugs and dementia risk: a case-control study. J. Alzheimers Dis. 66, 725\u2013732 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"390_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","volume":"181","author":"IK Wium-Andersen","year":"2019","unstructured":"Wium-Andersen, I. K., Osler, M., J\u00f8rgensen, M. B., Rungby, J. & Wium-Andersen, M. K. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case\u2013control study. Eur. J. Endocrinol. 181, 499\u2013507 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"390_CR51","doi-asserted-by":"publisher","unstructured":"Akimoto, H. et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. Am. J. Alzheimers Dis. Other Demen. https:\/\/doi.org\/10.1177\/1533317519899546 (2020).","DOI":"10.1177\/1533317519899546"},{"key":"390_CR52","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675 (2017).","journal-title":"Lancet"},{"key":"390_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J. Parkinsons Dis. 4, 337\u2013344 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"390_CR54","doi-asserted-by":"publisher","unstructured":"Hogg, E. et al. A phase ii, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease. Preprint at SSRN https:\/\/doi.org\/10.2139\/ssrn.4212371 (2022).","DOI":"10.2139\/ssrn.4212371"},{"key":"390_CR55","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185 (2024).","journal-title":"N. Engl. J. Med."},{"key":"390_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110688","volume":"200","author":"M Longo","year":"2023","unstructured":"Longo, M. et al. Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes. Diabetes Res. Clin. Pract. 200, 110688 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"390_CR57","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3233\/JAD-200618","volume":"76","author":"J Secnik","year":"2020","unstructured":"Secnik, J. et al. Dementia diagnosis is associated with changes in antidiabetic drug prescription: an open-cohort study of ~130,000 Swedish subjects over 14 years. J. Alzheimers Dis. 76, 1581\u20131594 (2020).","journal-title":"J. Alzheimers Dis."},{"key":"390_CR58","volume":"7","author":"B Zhou","year":"2021","unstructured":"Zhou, B. et al. Association between exenatide use and incidence of Alzheimer\u2019s disease. Alzheimers Dement. 7, e12139 (2021).","journal-title":"Alzheimers Dement."},{"key":"390_CR59","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/WNR.0000000000001071","volume":"29","author":"S Abtahi","year":"2018","unstructured":"Abtahi, S., Howell, E. & Currie, P. J. Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats. Neuroreport 29, 1046\u20131053 (2018).","journal-title":"Neuroreport"},{"key":"390_CR60","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1037\/pha0000620","volume":"31","author":"M-L Allingbjerg","year":"2023","unstructured":"Allingbjerg, M.-L., Hansen, S. N., Secher, A. & Thomsen, M. Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice. Exp. Clin. Psychopharmacol. 31, 612\u2013620 (2023).","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"390_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1180512","volume":"14","author":"C Aranas","year":"2023","unstructured":"Aranas, C., Blid Skoldheden, S. & Jerlhag, E. Antismoking agents do not contribute synergistically to semaglutide\u2019s ability to reduce alcohol intake in rats. Front. Pharmacol. 14, 1180512 (2023).","journal-title":"Front. Pharmacol."},{"key":"390_CR62","doi-asserted-by":"publisher","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","volume":"93","author":"C Aranas","year":"2023","unstructured":"Aranas, C. et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. eBioMedicine 93, 104642 (2023).","journal-title":"eBioMedicine"},{"key":"390_CR63","doi-asserted-by":"publisher","unstructured":"Bornebusch, A. B., Fink-Jensen, A., Wortwein, G., Seeley, R. J. & Thomsen, M. Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs. eNeuro https:\/\/doi.org\/10.1523\/ENEURO.0443-18.2019 (2019).","DOI":"10.1523\/ENEURO.0443-18.2019"},{"key":"390_CR64","doi-asserted-by":"publisher","unstructured":"Chuong, V. et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.170671 (2023).","DOI":"10.1172\/jci.insight.170671"},{"key":"390_CR65","doi-asserted-by":"publisher","unstructured":"Colvin, K. J. et al. Brain site-specific inhibitory effects of the GLP-1 analogue exendin-4 on alcohol intake and operant responding for palatable food. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21249710 (2020).","DOI":"10.3390\/ijms21249710"},{"key":"390_CR66","doi-asserted-by":"publisher","first-page":"113726","DOI":"10.1016\/j.bbr.2021.113726","volume":"421","author":"KJ Colvin","year":"2022","unstructured":"Colvin, K. J. et al. Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of d-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats. Behav. Brain Res. 421, 113726 (2022).","journal-title":"Behav. Brain Res."},{"key":"390_CR67","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.biopsych.2012.01.035","volume":"72","author":"JF Davis","year":"2012","unstructured":"Davis, J. F. et al. Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats. Biol. Psychiatry 72, 354\u2013360 (2012).","journal-title":"Biol. Psychiatry"},{"key":"390_CR68","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00213-023-06367-x","volume":"240","author":"C Diaz-Megido","year":"2023","unstructured":"Diaz-Megido, C. & Thomsen, M. Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL\/6J mice. Psychopharmacology 240, 1287\u20131298 (2023).","journal-title":"Psychopharmacology"},{"key":"390_CR69","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/acer.14437","volume":"44","author":"TN Dixon","year":"2020","unstructured":"Dixon, T. N., McNally, G. P. & Ong, Z. Y. Glucagon-like peptide-1 receptor signaling in the ventral tegmental area reduces alcohol self-administration in male rats. Alcohol. Clin. Exp. Res. 44, 2118\u20132129 (2020).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"390_CR70","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","volume":"38","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu, E. et al. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38, 1259\u20131270 (2013).","journal-title":"Psychoneuroendocrinology"},{"key":"390_CR71","doi-asserted-by":"crossref","unstructured":"Farokhnia, M. et al. The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: findings from human laboratory experiments and a post-mortem brain study. Addict. Biol. 27, e13211 (2022).","DOI":"10.1111\/adb.13211"},{"key":"390_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.599646","volume":"14","author":"VN Marty","year":"2020","unstructured":"Marty, V. N. et al. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Front. Neurosci. 14, 599646 (2020).","journal-title":"Front. Neurosci."},{"key":"390_CR73","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11011-014-9627-z","volume":"30","author":"AN Sharma","year":"2015","unstructured":"Sharma, A. N., Pise, A., Sharma, J. N. & Shukla, P. Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats. Metab. Brain Dis. 30, 719\u2013730 (2015).","journal-title":"Metab. Brain Dis."},{"key":"390_CR74","doi-asserted-by":"publisher","first-page":"e61965","DOI":"10.1371\/journal.pone.0061965","volume":"8","author":"RH Shirazi","year":"2013","unstructured":"Shirazi, R. H., Dickson, S. L. & Skibicka, K. P. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS ONE 8, e61965 (2013).","journal-title":"PLoS ONE"},{"key":"390_CR75","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/acer.13199","volume":"40","author":"G Sorensen","year":"2016","unstructured":"Sorensen, G., Caine, S. B. & Thomsen, M. Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice. Alcohol. Clin. Exp. Res. 40, 2247\u20132252 (2016).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"390_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.68","volume":"5","author":"P Suchankova","year":"2015","unstructured":"Suchankova, P. et al. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl. Psychiatry 5, e583 (2015).","journal-title":"Transl. Psychiatry"},{"key":"390_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","volume":"160","author":"M Thomsen","year":"2017","unstructured":"Thomsen, M. et al. The glucagon-like peptide 1 receptor agonist exendin-4 decreases relapse-like drinking in socially housed mice. Pharmacol. Biochem. Behav. 160, 14\u201320 (2017).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"390_CR78","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","volume":"236","author":"M Thomsen","year":"2019","unstructured":"Thomsen, M. et al. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology 236, 603\u2013611 (2019).","journal-title":"Psychopharmacology"},{"key":"390_CR79","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","volume":"103","author":"D Vallof","year":"2019","unstructured":"Vallof, D., Kalafateli, A. L. & Jerlhag, E. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. Psychoneuroendocrinology 103, 284\u2013295 (2019).","journal-title":"Psychoneuroendocrinology"},{"key":"390_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00923-1","volume":"10","author":"D Vallof","year":"2020","unstructured":"Vallof, D., Kalafateli, A. L. & Jerlhag, E. Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Transl. Psychiatry 10, 238 (2020).","journal-title":"Transl. Psychiatry"},{"key":"390_CR81","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/adb.12295","volume":"21","author":"D Vallof","year":"2016","unstructured":"Vallof, D. et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict. Biol. 21, 422\u2013437 (2016).","journal-title":"Addict. Biol."},{"key":"390_CR82","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","volume":"149","author":"D Vallof","year":"2019","unstructured":"Vallof, D., Vestlund, J. & Jerlhag, E. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. Neuropharmacology 149, 124\u2013132 (2019).","journal-title":"Neuropharmacology"},{"key":"390_CR83","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","volume":"33","author":"JE Douton","year":"2022","unstructured":"Douton, J. E. et al. Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats. Behav. Pharmacol. 33, 364\u2013378 (2022).","journal-title":"Behav. Pharmacol."},{"key":"390_CR84","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","volume":"32","author":"JE Douton","year":"2021","unstructured":"Douton, J. E. et al. Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats. Behav. Pharmacol. 32, 265\u2013277 (2021).","journal-title":"Behav. Pharmacol."},{"key":"390_CR85","doi-asserted-by":"publisher","first-page":"e13117","DOI":"10.1111\/adb.13117","volume":"27","author":"JE Douton","year":"2022","unstructured":"Douton, J. E. et al. Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats. Addict. Biol. 27, e13117 (2022).","journal-title":"Addict. Biol."},{"key":"390_CR86","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","volume":"189","author":"B Evans","year":"2022","unstructured":"Evans, B. et al. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats. Brain Res. Bull. 189, 163\u2013173 (2022).","journal-title":"Brain Res. Bull."},{"key":"390_CR87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","volume":"189","author":"LA Urbanik","year":"2022","unstructured":"Urbanik, L. A., Acharya, N. K. & Grigson, P. S. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats. Brain Res. Bull. 189, 155\u2013162 (2022).","journal-title":"Brain Res. Bull."},{"key":"390_CR88","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","volume":"45","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacology 45, 451\u2013461 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"390_CR89","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats. Neuropharmacology https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108599 (2021).","DOI":"10.1016\/j.neuropharm.2021.108599"},{"key":"390_CR90","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.drugalcdep.2017.07.033","volume":"180","author":"S Bouhlal","year":"2017","unstructured":"Bouhlal, S. et al. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug Alcohol Depend. 180, 68\u201375 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"390_CR91","doi-asserted-by":"publisher","first-page":"e69010","DOI":"10.1371\/journal.pone.0069010","volume":"8","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu, E., Engel, J. A. & Jerlhag, E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS ONE 8, e69010 (2013).","journal-title":"PLoS ONE"},{"key":"390_CR92","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","volume":"106","author":"K Erreger","year":"2012","unstructured":"Erreger, K. et al. Exendin-4 decreases amphetamine-induced locomotor activity. Physiol. Behav. 106, 574\u2013578 (2012).","journal-title":"Physiol. Behav."},{"key":"390_CR93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","volume":"176","author":"SM Fortin","year":"2017","unstructured":"Fortin, S. M. & Roitman, M. F. Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core. Physiol. Behav. 176, 17\u201325 (2017).","journal-title":"Physiol. Behav."},{"key":"390_CR94","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/mp.2012.141","volume":"18","author":"DL Graham","year":"2013","unstructured":"Graham, D. L., Erreger, K., Galli, A. & Stanwood, G. D. GLP-1 analog attenuates cocaine reward. Mol. Psychiatry 18, 961\u2013962 (2013).","journal-title":"Mol. Psychiatry"},{"key":"390_CR95","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/npp.2015.47","volume":"40","author":"AE Harasta","year":"2015","unstructured":"Harasta, A. E. et al. Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior. Neuropsychopharmacology 40, 1969\u20131978 (2015).","journal-title":"Neuropsychopharmacology"},{"key":"390_CR96","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","volume":"43","author":"NS Hernandez","year":"2018","unstructured":"Hernandez, N. S. et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology 43, 2000\u20132008 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"390_CR97","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/adb.12583","volume":"24","author":"NS Hernandez","year":"2019","unstructured":"Hernandez, N. S., O\u2019Donovan, B., Ortinski, P. I. & Schmidt, H. D. Activation of glucagon-like peptide-I receptors in the nucleus accumbens attenuates cocaine seeking in rats. Addict. Biol. 24, 170\u2013181 (2019).","journal-title":"Addict. Biol."},{"key":"390_CR98","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","volume":"26","author":"NS Hernandez","year":"2021","unstructured":"Hernandez, N. S. et al. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA. Mol. Psychiatry 26, 4394\u20134408 (2021).","journal-title":"Mol. Psychiatry"},{"key":"390_CR99","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1038\/tp.2016.86","volume":"6","author":"IA Reddy","year":"2016","unstructured":"Reddy, I. A. et al. Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Transl. Psychiatry 6, e809 (2016).","journal-title":"Transl. Psychiatry"},{"key":"390_CR100","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/npp.2015.362","volume":"41","author":"HD Schmidt","year":"2016","unstructured":"Schmidt, H. D. et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine. Neuropsychopharmacology 41, 1917\u20131928 (2016).","journal-title":"Neuropsychopharmacology"},{"key":"390_CR101","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","volume":"161","author":"S Sirohi","year":"2016","unstructured":"Sirohi, S., Schurdak, J. D., Seeley, R. J., Benoit, S. C. & Davis, J. F. Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol. Behav. 161, 140\u2013144 (2016).","journal-title":"Physiol. Behav."},{"key":"390_CR102","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","volume":"149","author":"G Sorensen","year":"2015","unstructured":"Sorensen, G. et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol. Behav. 149, 262\u2013268 (2015).","journal-title":"Physiol. Behav."},{"key":"390_CR103","doi-asserted-by":"publisher","unstructured":"Zhu, C. et al. Glucagon-like peptide-1 agonist exendin-4 facilitates the extinction of cocaine-induced condition place preference. Front. Syst. Neurosci. https:\/\/doi.org\/10.3389\/fnsys.2021.711750 (2021).","DOI":"10.3389\/fnsys.2021.711750"},{"key":"390_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.694476","volume":"12","author":"C Zhu","year":"2021","unstructured":"Zhu, C. et al. Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting toll-like receptor 4 signaling in mice. Front. Pharmacol. 12, 694476 (2021).","journal-title":"Front. Pharmacol."},{"key":"390_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.769664","volume":"15","author":"C Zhu","year":"2021","unstructured":"Zhu, C. et al. Effects of glucagon-like peptide-1 receptor agonist exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice. Front. Behav. Neurosci. 15, 769664 (2021).","journal-title":"Front. Behav. Neurosci."},{"key":"390_CR106","doi-asserted-by":"publisher","first-page":"e77284","DOI":"10.1371\/journal.pone.0077284","volume":"8","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu, E., Engel, J. A. & Jerlhag, E. The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS ONE 8, e77284 (2013).","journal-title":"PLoS ONE"},{"key":"390_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112466","volume":"42","author":"S Falk","year":"2023","unstructured":"Falk, S. et al. GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Rep. 42, 112466 (2023).","journal-title":"Cell Rep."},{"key":"390_CR108","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","volume":"240","author":"RJ Herman","year":"2023","unstructured":"Herman, R. J., Hayes, M. R., Audrain-McGovern, J., Ashare, R. L. & Schmidt, H. D. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology 240, 1373\u20131386 (2023).","journal-title":"Psychopharmacology"},{"key":"390_CR109","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nn.4540","volume":"20","author":"LM Tuesta","year":"2017","unstructured":"Tuesta, L. M. et al. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat. Neurosci. 20, 708\u2013716 (2017).","journal-title":"Nat. Neurosci."},{"key":"390_CR110","doi-asserted-by":"publisher","unstructured":"Jerlhag, E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1063033 (2023).","DOI":"10.3389\/fphar.2023.1063033"},{"key":"390_CR111","doi-asserted-by":"publisher","unstructured":"Klausen, M. K. et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.159863 (2022).","DOI":"10.1172\/jci.insight.159863"},{"key":"390_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat. Commun. 15, 4548 (2024).","journal-title":"Nat. Commun."},{"key":"390_CR113","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcpt.13776","volume":"131","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen, I. K. et al. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin. Pharmacol. Toxicol. 131, 372\u2013379 (2022).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"390_CR114","doi-asserted-by":"publisher","unstructured":"Wang, W. et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-024-02498-5 (2024).","DOI":"10.1038\/s41380-024-02498-5"},{"key":"390_CR115","doi-asserted-by":"publisher","unstructured":"Angarita, G. A. et al. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108614 (2021).","DOI":"10.1016\/j.drugalcdep.2021.108614"},{"key":"390_CR116","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","volume":"17","author":"L Yammine","year":"2023","unstructured":"Yammine, L., Balderas, J. C., Weaver, M. F. & Schmitz, J. M. Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study. J. Addict. Med. 17, 481\u2013484 (2023).","journal-title":"J. Addict. Med."},{"key":"390_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101865","volume":"57","author":"S Lengsfeld","year":"2023","unstructured":"Lengsfeld, S. et al. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. eClinicalMedicine 57, 101865 (2023).","journal-title":"eClinicalMedicine"},{"key":"390_CR118","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","volume":"23","author":"L Yammine","year":"2021","unstructured":"Yammine, L. et al. Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial. Nicotine Tob. Res. 23, 1682\u20131690 (2021).","journal-title":"Nicotine Tob. Res."},{"key":"390_CR119","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.physbeh.2013.03.008","volume":"114-115","author":"TS Dixit","year":"2013","unstructured":"Dixit, T. S., Sharma, A. N., Lucot, J. B. & Elased, K. M. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol. Behav. 114-115, 38\u201341 (2013).","journal-title":"Physiol. Behav."},{"key":"390_CR120","doi-asserted-by":"publisher","first-page":"114386","DOI":"10.1016\/j.bbr.2023.114386","volume":"445","author":"MD Kutlu","year":"2023","unstructured":"Kutlu, M. D., Kose, S. & Akillioglu, K. GLP-1 agonist liraglutide prevents MK-801-induced schizophrenia-like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb\/c mice. Behav. Brain Res. 445, 114386 (2023).","journal-title":"Behav. Brain Res."},{"key":"390_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119523","volume":"278","author":"AA Sedky","year":"2021","unstructured":"Sedky, A. A. & Magdy, Y. Reduction in TNF alpha and oxidative stress by liraglutide: impact on ketamine-induced cognitive dysfunction and hyperlocomotion in rats. Life Sci. 278, 119523 (2021).","journal-title":"Life Sci."},{"key":"390_CR122","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0269881118756061","volume":"32","author":"I Babic","year":"2018","unstructured":"Babic, I. et al. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. J. Psychopharmacol. 32, 578\u2013590 (2018).","journal-title":"J. Psychopharmacol."},{"key":"390_CR123","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1177\/0269881120981377","volume":"35","author":"I Babic","year":"2021","unstructured":"Babic, I. et al. Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats. J. Psychopharmacol. 35, 284\u2013302 (2021).","journal-title":"J. Psychopharmacol."},{"key":"390_CR124","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41401-021-00680-x","volume":"42","author":"D-J Li","year":"2021","unstructured":"Li, D.-J. et al. Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1\/GLP1R signaling in rats. Acta Pharmacol. Sin. 42, 1267\u20131279 (2021).","journal-title":"Acta Pharmacol. Sin."},{"key":"390_CR125","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","volume":"103","author":"K Lykkegaard","year":"2008","unstructured":"Lykkegaard, K. et al. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr. Res. 103, 94\u2013103 (2008).","journal-title":"Schizophr. Res."},{"key":"390_CR126","doi-asserted-by":"publisher","first-page":"E1101","DOI":"10.1152\/ajpendo.00309.2020","volume":"319","author":"KD Medak","year":"2020","unstructured":"Medak, K. D., Shamshoum, H., Peppler, W. T. & Wright, D. C. GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia. Am. J. Physiol. Endocrinol. Metab. 319, E1101\u2013E1111 (2020).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"390_CR127","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","volume":"30","author":"AN Sharma","year":"2015","unstructured":"Sharma, A. N. et al. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab. Brain Dis. 30, 519\u2013527 (2015).","journal-title":"Metab. Brain Dis."},{"key":"390_CR128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","volume":"115","author":"GC Smith","year":"2009","unstructured":"Smith, G. C., Vickers, M. H., Cognard, E. & Shepherd, P. R. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr. Res. 115, 30\u201340 (2009).","journal-title":"Schizophr. Res."},{"key":"390_CR129","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.schres.2014.05.003","volume":"157","author":"GC Smith","year":"2014","unstructured":"Smith, G. C. et al. Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance. Schizophr. Res. 157, 128\u2013133 (2014).","journal-title":"Schizophr. Res."},{"key":"390_CR130","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bbi.2018.03.013","volume":"70","author":"L Bocchio-Chiavetto","year":"2018","unstructured":"Bocchio-Chiavetto, L. et al. Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain Behav. Immun. 70, 315\u2013324 (2018).","journal-title":"Brain Behav. Immun."},{"key":"390_CR131","doi-asserted-by":"publisher","unstructured":"Klemettila, J.-P. et al. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. Psychiatry Res. https:\/\/doi.org\/10.1016\/j.psychres.2021.114227 (2021).","DOI":"10.1016\/j.psychres.2021.114227"},{"key":"390_CR132","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.schres.2014.09.038","volume":"160","author":"TL Ramsey","year":"2014","unstructured":"Ramsey, T. L. & Brennan, M. D. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. Schizophr. Res. 160, 73\u201379 (2014).","journal-title":"Schizophr. Res."},{"key":"390_CR133","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/acps.12711","volume":"136","author":"PL Ishoy","year":"2017","unstructured":"Ishoy, P. L. et al. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr. Scand. 136, 52\u201362 (2017).","journal-title":"Acta Psychiatr. Scand."},{"key":"390_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1153648","volume":"14","author":"A Khaity","year":"2023","unstructured":"Khaity, A. et al. Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis. Front. Psychiatry 14, 1153648 (2023).","journal-title":"Front. Psychiatry"},{"key":"390_CR135","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/biomedicines11030669","volume":"11","author":"D Patoulias","year":"2023","unstructured":"Patoulias, D. et al. Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials. Biomedicines 11, 669 (2023).","journal-title":"Biomedicines"},{"key":"390_CR136","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","volume":"21","author":"D Siskind","year":"2019","unstructured":"Siskind, D. et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes. Metab. 21, 293\u2013302 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR137","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/02698811211035391","volume":"35","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis. J. Psychopharmacol. 35, 1111\u20131119 (2021).","journal-title":"J. Psychopharmacol."},{"key":"390_CR138","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","volume":"20","author":"DJ Siskind","year":"2018","unstructured":"Siskind, D. J. et al. Treatment of clozapine\u2010associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes. Metab. 20, 1050\u20131055 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR139","doi-asserted-by":"publisher","unstructured":"Eriksson, R. et al. Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density. Front. Psychiatry https:\/\/doi.org\/10.3389\/fpsyt.2018.00781 (2019).","DOI":"10.3389\/fpsyt.2018.00781"},{"key":"390_CR140","doi-asserted-by":"crossref","unstructured":"Ish\u00f8y, P. L. et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes. Metab. 19, 162\u2013171 (2017).","DOI":"10.1111\/dom.12795"},{"key":"390_CR141","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen, J. R. et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 74, 719\u2013728 (2017).","journal-title":"JAMA Psychiatry"},{"key":"390_CR142","doi-asserted-by":"publisher","unstructured":"Maagensen, H., Larsen, J. R., Jorgensen, N. R., Fink-Jensen, A. & Vilsboll, T. Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes\u2014randomized controlled trial. Psychiatry Res. https:\/\/doi.org\/10.1016\/j.psychres.2020.113670 (2021).","DOI":"10.1016\/j.psychres.2020.113670"},{"key":"390_CR143","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/acps.12982","volume":"139","author":"CK Svensson","year":"2019","unstructured":"Svensson, C. K. et al. One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr. Scand. 139, 26\u201336 (2019).","journal-title":"Acta Psychiatr. Scand."},{"key":"390_CR144","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","volume":"23","author":"CA Whicher","year":"2021","unstructured":"Whicher, C. A. et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 23, 1262\u20131271 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR145","unstructured":"Exenatide for the treatment of weight gain associated with olanzapine in obese adults. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT00845507 (2018)."},{"key":"390_CR146","unstructured":"Patino, L. R. et al. A double-blind placebo-controlled study of exenatide for the treatment of weight gain associated with olanzapine in overweight or obese adults with bipolar disorder, major depressive disorder, schizophrenia or schizoaffective disorder. Biol. Psychiatry 77, 132S (2015)."},{"key":"390_CR147","doi-asserted-by":"crossref","unstructured":"Siskind, D. et al. Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX). J. Psychiatr. Res. 124, 9\u201312 (2020).","DOI":"10.1016\/j.jpsychires.2020.02.015"},{"key":"390_CR148","unstructured":"Ando, T. et al. Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics. Acta Med. Nagasaki 61, 151\u2013157 (2018)."},{"key":"390_CR149","doi-asserted-by":"publisher","unstructured":"Lee, S. E., Lee, N. Y., Kim, S. H., Kim, K.-A. & Kim, Y. S. Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients. Psychiatry Res. https:\/\/doi.org\/10.1016\/j.psychres.2021.113830 (2021).","DOI":"10.1016\/j.psychres.2021.113830"},{"key":"390_CR150","doi-asserted-by":"publisher","unstructured":"Perlis, L. T., Lamberti, J. S. & Miedlich, S. U. Glucagon-like peptide analogs are superior for diabetes and weight control in patients on antipsychotic medications: a retrospective cohort study. Prim. Care Companion CNS Disord. https:\/\/doi.org\/10.4088\/PCC.19m02504 (2020).","DOI":"10.4088\/PCC.19m02504"},{"key":"390_CR151","doi-asserted-by":"crossref","unstructured":"Ishoy, P. L., Knop, F. K., Vilsboll, T., Glenthoj, B. Y. & Ebdrup, B. H. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am. J. Psychiatry 170, 681\u2013682 (2013).","DOI":"10.1176\/appi.ajp.2013.12101344"},{"key":"390_CR152","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s13340-022-00590-1","volume":"13","author":"K Noda","year":"2022","unstructured":"Noda, K. et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetol. Int. 13, 693\u2013697 (2022).","journal-title":"Diabetol. Int."},{"key":"390_CR153","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231165169","volume":"13","author":"F Prasad","year":"2023","unstructured":"Prasad, F. et al. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin\u2014a case series. Ther. Adv. Psychopharmacol. 13, 20451253231165169 (2023).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"390_CR154","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/0004867416636243","volume":"50","author":"D Siskind","year":"2016","unstructured":"Siskind, D., Wysoczanski, D., Russell, A. & Ashford, M. Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine. Aust. N. Z. J. Psychiatry 50, 702\u2013703 (2016).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"390_CR155","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.12998\/wjcc.v10.i21.7495","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang, L., Yu, W.-J., Zhu, H., Li, H.-F. & Qiao, J. Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: a case report. World J. Clin. Cases 10, 7495\u20137501 (2022).","journal-title":"World J. Clin. Cases"},{"key":"390_CR156","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/10799893.2022.2032747","volume":"42","author":"MN Cicekli","year":"2022","unstructured":"Cicekli, M. N., Tiryaki, E. S., Altun, A. & Gunaydin, C. GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3beta pathway. J. Recept. Signal Transduct. Res. 42, 486\u2013494 (2022).","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"390_CR157","doi-asserted-by":"publisher","unstructured":"Chaves Filho, A. J. M. et al. The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by d-amphetamine and augments lithium effects in mice: relevance for bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109872 (2020).","DOI":"10.1016\/j.pnpbp.2020.109872"},{"key":"390_CR158","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","volume":"65","author":"RH Anderberg","year":"2016","unstructured":"Anderberg, R. H. et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 65, 54\u201366 (2016).","journal-title":"Psychoneuroendocrinology"},{"key":"390_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108246","volume":"123","author":"H Aygun","year":"2021","unstructured":"Aygun, H. Exendin-4 increases absence-like seizures and anxiety-depression-like behaviors in WAG\/Rij rats. Epilepsy Behav. 123, 108246 (2021).","journal-title":"Epilepsy Behav."},{"key":"390_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121546","volume":"320","author":"AB Darwish","year":"2023","unstructured":"Darwish, A. B., El Sayed, N. S., Salama, A. A. A. & Saad, M. A. Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL\/6 mice: implications on GLP-1R and cAMP\/PKA signaling pathway in the hippocampus. Life Sci. 320, 121546 (2023).","journal-title":"Life Sci."},{"key":"390_CR161","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.biopha.2018.10.066","volume":"109","author":"AG de Souza","year":"2019","unstructured":"de Souza, A. G. et al. Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: involvement of brain antioxidant and BDNF upregulating properties. Biomed. Pharmacother. 109, 429\u2013439 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"390_CR162","doi-asserted-by":"crossref","unstructured":"Krass, M. et al. GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment. Acta Neuropsychiatr. 27, 25\u201332 (2015).","DOI":"10.1017\/neu.2014.36"},{"key":"390_CR163","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.18632\/aging.202358","volume":"13","author":"G Ren","year":"2021","unstructured":"Ren, G., Xue, P., Wu, B., Yang, F. & Wu, X. Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via CREB-mediated adult neurogenesis in mouse depression model. Aging 13, 3898\u20133908 (2021).","journal-title":"Aging"},{"key":"390_CR164","doi-asserted-by":"crossref","unstructured":"Saglam, C., Turan, I. & Ozacmak, H. S. The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: modulation of BDNF\/CREB, Nrf2 and lipocalin 2. Behav. Brain Res. 435, 114053 (2022).","DOI":"10.1016\/j.bbr.2022.114053"},{"key":"390_CR165","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jad.2022.12.089","volume":"324","author":"MK Seo","year":"2023","unstructured":"Seo, M. K. et al. Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test. J. Affect. Disord. 324, 8\u201315 (2023).","journal-title":"J. Affect. Disord."},{"key":"390_CR166","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.brainresbull.2021.06.011","volume":"174","author":"I Turan","year":"2021","unstructured":"Turan, I., Sayan Ozacmak, H., Ozacmak, V. H., Ergenc, M. & Bayraktaroglu, T. The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation. Brain Res. Bull. 174, 194\u2013202 (2021).","journal-title":"Brain Res. Bull."},{"key":"390_CR167","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.brainres.2018.04.031","volume":"1694","author":"H Weina","year":"2018","unstructured":"Weina, H. et al. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res. 1694, 55\u201362 (2018).","journal-title":"Brain Res."},{"key":"390_CR168","doi-asserted-by":"publisher","unstructured":"Yang, F. et al. Glucagon-like peptide 1 receptor activation inhibits microglial pyroptosis via promoting mitophagy to alleviate depression-like behaviors in diabetic mice. Nutrients https:\/\/doi.org\/10.3390\/nu15010038 (2022).","DOI":"10.3390\/nu15010038"},{"key":"390_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104720","volume":"119","author":"L L\u00f3pez-Ferreras","year":"2020","unstructured":"L\u00f3pez-Ferreras, L. et al. The supramammillary nucleus controls anxiety-like behavior; key role of GLP-1R. Psychoneuroendocrinology 119, 104720 (2020).","journal-title":"Psychoneuroendocrinology"},{"key":"390_CR170","first-page":"1391","volume":"56","author":"ZQ Hu","year":"2021","unstructured":"Hu, Z. Q. et al. Puerarin ameliorates depressive symptoms in diabetic mice induced by high-fat diet. Yao Xue Xue Bao 56, 1391\u20131399 (2021).","journal-title":"Yao Xue Xue Bao"},{"key":"390_CR171","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbr.2009.06.020","volume":"204","author":"T Iwai","year":"2009","unstructured":"Iwai, T. et al. Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways. Behav. Brain Res. 204, 235\u2013240 (2009).","journal-title":"Behav. Brain Res."},{"key":"390_CR172","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbr.2013.01.010","volume":"243","author":"T Iwai","year":"2013","unstructured":"Iwai, T. et al. Glucagon-like peptide-2 but not imipramine exhibits antidepressant-like effects in ACTH-treated mice. Behav. Brain Res. 243, 153\u2013157 (2013).","journal-title":"Behav. Brain Res."},{"key":"390_CR173","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/1028415X.2022.2112439","volume":"26","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Hu, Z., Wang, J., Liao, Y. & Shu, L. Puerarin alleviates depressive-like behaviors in high-fat diet-induced diabetic mice via modulating hippocampal GLP-1R\/BDNF\/TrkB signaling. Nutr. Neurosci. 26, 997\u20131010 (2023).","journal-title":"Nutr. Neurosci."},{"key":"390_CR174","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neures.2020.05.003","volume":"165","author":"B Sun","year":"2021","unstructured":"Sun, B., Jia, X., Yang, F., Ren, G. & Wu, X. CREB-mediated generation and neuronal growth regulates the behavioral improvement of geniposide in diabetes-associated depression mouse model. Neurosci. Res. 165, 38\u201344 (2021).","journal-title":"Neurosci. Res."},{"key":"390_CR175","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2018.04.010","volume":"676","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Geniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R\/AKT signaling pathway. Neurosci. Lett. 676, 19\u201326 (2018).","journal-title":"Neurosci. Lett."},{"key":"390_CR176","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.euroneuro.2018.10.007","volume":"29","author":"RB Mansur","year":"2019","unstructured":"Mansur, R. B. et al. The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. Eur. Neuropsychopharmacol. 29, 137\u2013146 (2019).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"390_CR177","doi-asserted-by":"publisher","unstructured":"Verovnik, B. & Vovk, A. Semaglutide, suicidal ideation and behaviour: a resting state functional magnetic resonance imaging perspective. Diabetes Obes. Metab. https:\/\/doi.org\/10.1111\/dom.15363 (2023).","DOI":"10.1111\/dom.15363"},{"key":"390_CR178","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","volume":"207","author":"RB Mansur","year":"2017","unstructured":"Mansur, R. B. et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J. Affect. Disord. 207, 114\u2013120 (2017).","journal-title":"J. Affect. Disord."},{"key":"390_CR179","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.euroneuro.2017.08.433","volume":"27","author":"RB Mansur","year":"2017","unstructured":"Mansur, R. B. et al. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur. Neuropsychopharmacol. 27, 1153\u20131162 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"390_CR180","doi-asserted-by":"publisher","unstructured":"Cuomo, A. et al. Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Front. Psychiatry https:\/\/doi.org\/10.3389\/fpsyt.2018.00784 (2019).","DOI":"10.3389\/fpsyt.2018.00784"},{"key":"390_CR181","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/gps.1937","volume":"23","author":"I Kohen","year":"2008","unstructured":"Kohen, I. & Lester, P. Exenatide-induced depression in a geriatric patient. Int. J. Geriatr. Psychiatry 23, 443\u2013444 (2008).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"390_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1238353","volume":"14","author":"J-R Li","year":"2023","unstructured":"Li, J.-R., Cao, J., Wei, J. & Geng, W. Case report: semaglutide-associated depression: a report of two cases. Front. Psychiatry 14, 1238353 (2023).","journal-title":"Front. Psychiatry"},{"key":"390_CR183","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2337\/dc10-1119","volume":"34","author":"JH Best","year":"2011","unstructured":"Best, J. H. et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care 34, 314\u2013319 (2011).","journal-title":"Diabetes Care"},{"key":"390_CR184","doi-asserted-by":"crossref","unstructured":"Bode, B. W. et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes. Metab. 12, 604\u2013612 (2010).","DOI":"10.1111\/j.1463-1326.2010.01196.x"},{"key":"390_CR185","doi-asserted-by":"crossref","unstructured":"de Wit, H. M. et al. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia 57, 1812\u20131819 (2014).","DOI":"10.1007\/s00125-014-3302-0"},{"key":"390_CR186","doi-asserted-by":"crossref","unstructured":"Miras, A. D. et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 7, 549\u2013559 (2019).","DOI":"10.1016\/S2213-8587(19)30157-3"},{"key":"390_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-217","volume":"11","author":"M Reaney","year":"2013","unstructured":"Reaney, M. et al. Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health Qual. Life Outcomes 11, 217 (2013).","journal-title":"Health Qual. Life Outcomes"},{"key":"390_CR188","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","volume":"32","author":"X Chen","year":"2024","unstructured":"Chen, X., Zhao, P., Wang, W., Guo, L. & Pan, Q. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Am. J. Geriat. Psychiatry 32, 117\u2013127 (2024).","journal-title":"Am. J. Geriat. Psychiatry"},{"key":"390_CR189","doi-asserted-by":"crossref","unstructured":"de Wit, H. M., Vervoort, G. M., Jansen, H. J., de Galan, B. E. & Tack, C. J. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the effect of liraglutide on insulin-associated weight gain in patients with type 2 diabetes\u2019 (ELEGANT) randomized controlled trial. J. Intern. Med. 279, 283\u2013292 (2016).","DOI":"10.1111\/joim.12447"},{"key":"390_CR190","doi-asserted-by":"crossref","unstructured":"Grant, P., Lipscomb, D. & Quin, J. Psychological and quality of life changes in patients using GLP-1 analogues. J. Diabetes Complications 25, 244\u2013246 (2011).","DOI":"10.1016\/j.jdiacomp.2011.03.002"},{"key":"390_CR191","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2869.2012.01030.x","volume":"22","author":"I Idris","year":"2013","unstructured":"Idris, I., Abdulla, H., Tilbrook, S., Dean, R. & Ali, N. Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea. J. Sleep Res. 22, 70\u201375 (2013).","journal-title":"J. Sleep Res."},{"key":"390_CR192","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pcd.2015.06.003","volume":"10","author":"CD Moulton","year":"2016","unstructured":"Moulton, C. D., Pickup, J. C., Amiel, S. A., Winkley, K. & Ismail, K. Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: findings from the South London Diabetes (SOUL-D) study. Prim. Care Diabetes 10, 156\u2013159 (2016).","journal-title":"Prim. Care Diabetes"},{"key":"390_CR193","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","volume":"19","author":"PM O\u2019Neil","year":"2017","unstructured":"O\u2019Neil, P. M. et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes. Metab. 19, 1529\u20131536 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR194","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2174\/18715303113139990037","volume":"13","author":"I Tasci","year":"2013","unstructured":"Tasci, I. et al. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr. Metab. Immune Disord. Drug Targets 13, 256\u2013263 (2013).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"390_CR195","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jad.2019.05.044","volume":"257","author":"M Pozzi","year":"2019","unstructured":"Pozzi, M. et al. A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: further link between metabolism and psychopathology: special section on \u201cTranslational and neuroscience studies in affective disorders\u201d. J. Affect. Disord. 257, 774\u2013778 (2019).","journal-title":"J. Affect. Disord."},{"key":"390_CR196","doi-asserted-by":"crossref","unstructured":"Astrup, A. et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606\u20131616 (2009).","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"390_CR197","doi-asserted-by":"crossref","unstructured":"Blackman, A. et al. Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int. J. Obes. 40, 1310\u20131319 (2016).","DOI":"10.1038\/ijo.2016.52"},{"key":"390_CR198","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies, M. J. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314, 687\u2013699 (2015).","journal-title":"JAMA"},{"key":"390_CR199","doi-asserted-by":"crossref","unstructured":"Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11\u201322 (2015).","DOI":"10.1056\/NEJMoa1411892"},{"key":"390_CR200","doi-asserted-by":"crossref","unstructured":"Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int. J. Obes. 37, 1443\u20131451 (2013).","DOI":"10.1038\/ijo.2013.120"},{"key":"390_CR201","doi-asserted-by":"publisher","first-page":"e023830","DOI":"10.1136\/bmjopen-2018-023830","volume":"8","author":"J-M Gamble","year":"2018","unstructured":"Gamble, J.-M., Chibrikov, E., Midodzi, W. K., Twells, L. K. & Majumdar, S. R. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open 8, e023830 (2018).","journal-title":"BMJ Open"},{"key":"390_CR202","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.2337\/dc20-1561","volume":"43","author":"LV Kessing","year":"2020","unstructured":"Kessing, L. V. et al. Antidiabetes agents and incident depression: a nationwide population-based study. Diabetes Care 43, 3050\u20133060 (2020).","journal-title":"Diabetes Care"},{"key":"390_CR203","doi-asserted-by":"publisher","first-page":"105715","DOI":"10.1016\/j.psyneuen.2022.105715","volume":"140","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen, I. K., Osler, M., Jorgensen, M. B., Rungby, J. & Wium-Andersen, M. K. Diabetes, antidiabetic medications and risk of depression\u2014a population-based cohort and nested case-control study. Psychoneuroendocrinology 140, 105715 (2022).","journal-title":"Psychoneuroendocrinology"},{"key":"390_CR204","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/09513590.2018.1505848","volume":"35","author":"H Kahal","year":"2019","unstructured":"Kahal, H., Kilpatrick, E., Rigby, A., Coady, A. & Atkin, S. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls. Gynecol. Endocrinol. 35, 142\u2013145 (2019).","journal-title":"Gynecol. Endocrinol."},{"key":"390_CR205","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/JCP.0000000000001409","volume":"41","author":"CY Eren-Yazicioglu","year":"2021","unstructured":"Eren-Yazicioglu, C. Y. et al. Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores through increased perceived stress levels. J. Clin. Psychopharmacol. 41, 428\u2013435 (2021).","journal-title":"J. Clin. Psychopharmacol."},{"key":"390_CR206","unstructured":"European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. EMA https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists (2023)."},{"key":"390_CR207","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/ph17020147","volume":"17","author":"R Ruggiero","year":"2024","unstructured":"Ruggiero, R. et al. Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the european pharmacovigilance database. Pharmaceuticals 17, 147 (2024).","journal-title":"Pharmaceuticals"},{"key":"390_CR208","doi-asserted-by":"publisher","unstructured":"Tang, H. et al. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes. Ann. Intern. Med. https:\/\/doi.org\/10.7326\/m24-0329 (2024).","DOI":"10.7326\/m24-0329"},{"key":"390_CR209","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat. Med. 30, 168\u2013176 (2024).","journal-title":"Nat. Med."},{"key":"390_CR210","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1172\/JCI74726","volume":"124","author":"X Cao","year":"2014","unstructured":"Cao, X. et al. Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice. J. Clin. Invest. 124, 4351\u20134362 (2014).","journal-title":"J. Clin. Invest."},{"key":"390_CR211","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.physbeh.2016.12.034","volume":"171","author":"E Yamaguchi","year":"2017","unstructured":"Yamaguchi, E., Yasoshima, Y. & Shimura, T. Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice. Physiol. Behav. 171, 158\u2013164 (2017).","journal-title":"Physiol. Behav."},{"key":"390_CR212","doi-asserted-by":"publisher","unstructured":"Mukherjee, A., Hum, A., Gustafson, T. J. & Mietlicki-Baase, E. G. Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius. Physiol. Behav. https:\/\/doi.org\/10.1016\/j.physbeh.2020.112830 (2020).","DOI":"10.1016\/j.physbeh.2020.112830"},{"key":"390_CR213","doi-asserted-by":"crossref","unstructured":"Pierce-Messick, Z. & Pratt, W. E. Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by micro-opioid receptor stimulation of the nucleus accumbens in the rat. Neuroreport 31, 1283\u20131288 (2020).","DOI":"10.1097\/WNR.0000000000001545"},{"key":"390_CR214","doi-asserted-by":"publisher","unstructured":"Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future medications for obesity? Int. J. Obes. https:\/\/doi.org\/10.1038\/s41366-024-01473-y (2024).","DOI":"10.1038\/s41366-024-01473-y"},{"key":"390_CR215","doi-asserted-by":"crossref","unstructured":"Chao, A. M. et al. Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology. Obesity 27, 2005\u20132010 (2019).","DOI":"10.1002\/oby.22653"},{"key":"390_CR216","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/07435800.2014.966385","volume":"40","author":"M Jensterle","year":"2015","unstructured":"Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M. & Janez, A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr. Res. 40, 133\u2013138 (2015).","journal-title":"Endocr. Res."},{"key":"390_CR217","doi-asserted-by":"publisher","first-page":"113967","DOI":"10.1016\/j.physbeh.2022.113967","volume":"257","author":"J Nicolau","year":"2022","unstructured":"Nicolau, J., Pujol, A., Tofe, S., Bonet, A. & Gil, A. Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity. Physiol. Behav. 257, 113967 (2022).","journal-title":"Physiol. Behav."},{"key":"390_CR218","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/osp4.619","volume":"9","author":"KC Allison","year":"2023","unstructured":"Allison, K. C. et al. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obes. Sci. Pract. 9, 127\u2013136 (2023).","journal-title":"Obes. Sci. Pract."},{"key":"390_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080","volume":"7","author":"J Richards","year":"2023","unstructured":"Richards, J. et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes. Pillars 7, 100080 (2023).","journal-title":"Obes. Pillars"},{"key":"390_CR220","doi-asserted-by":"crossref","unstructured":"Robert, S. A. et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide\u2014a pilot study. Obes. Clin. Res. Pract. 9, 301\u2013304 (2015).","DOI":"10.1016\/j.orcp.2015.03.005"},{"key":"390_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882","volume":"58","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura, M. et al. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine 58, 101882 (2023).","journal-title":"eClinicalMedicine"},{"key":"390_CR222","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","volume":"14","author":"A Da Porto","year":"2020","unstructured":"Da Porto, A. et al. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes Metab. Syndr. 14, 289\u2013292 (2020).","journal-title":"Diabetes Metab. Syndr."},{"key":"390_CR223","unstructured":"Weisenthal, J. & Alloway, T. GLP-1 drugs are coming, and they could change everything. Bloomberg https:\/\/www.bloomberg.com\/news\/articles\/2023-08-18\/glp-1-drugs-are-coming-and-they-could-change-everything?embedded-checkout=true (2023)."},{"key":"390_CR224","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/dom.15538","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii, G. A., Marinelli, C., Mannucci, E. & Rotella, F. Glucagon-like peptide-1 receptor agonists and mental health: a meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 26, 2505\u20132508 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR225","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1192\/j.eurpsy.2023.2474","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen, C., Zhou, R., Fu, F. & Xiao, J. Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur. Psychiatry 66, e99 (2023).","journal-title":"Eur. Psychiatry"},{"key":"390_CR226","doi-asserted-by":"publisher","unstructured":"Chen, W., Cai, P., Zou, W. & Fu, Z. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Front. Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2024.1330936 (2024).","DOI":"10.3389\/fendo.2024.1330936"},{"key":"390_CR227","doi-asserted-by":"publisher","unstructured":"De Giorgi, R. et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine https:\/\/doi.org\/10.1016\/j.eclinm.2024.102726 (2024).","DOI":"10.1016\/j.eclinm.2024.102726"},{"key":"390_CR228","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","volume":"46","author":"M Tobaiqy","year":"2024","unstructured":"Tobaiqy, M. & Elkout, H. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int. J. Clin. Pharm. 46, 488\u2013495 (2024).","journal-title":"Int. J. Clin. Pharm."},{"key":"390_CR229","doi-asserted-by":"publisher","unstructured":"Zhou, J. et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med. https:\/\/doi.org\/10.1186\/s12916-024-03274-6 (2024).","DOI":"10.1186\/s12916-024-03274-6"},{"key":"390_CR230","unstructured":"Fick, M. Exclusive: UK probes Novo\u2019s Ozempic, weight-loss drug Saxenda over suicidal, self-harming thoughts. Reuters https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/uk-probing-novos-ozempic-weight-loss-drug-saxenda-over-suicidal-self-harming-2023-07-26\/ (2023)."},{"key":"390_CR231","unstructured":"Tchang, B. G., Aras, M., Kumar, R. B. & Aronne, L. J. Pharmacologic Treatment of Overweight and Obesity in Adults (MDText.com, 2021)."},{"key":"390_CR232","unstructured":"Bendix, A. Should Ozempic come with a warning about a risk of suicidal thoughts? NBC News https:\/\/www.nbcnews.com\/health\/health-news\/ozempic-wegovy-reports-suicidal-thoughts-rcna93919 (2023)."},{"key":"390_CR233","doi-asserted-by":"publisher","unstructured":"McCartney, M. Semaglutide: should the media slim down its enthusiasm? BMJ https:\/\/doi.org\/10.1136\/bmj.p624 (2023).","DOI":"10.1136\/bmj.p624"},{"key":"390_CR234","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller, T. D., Bl\u00fcher, M., Tsch\u00f6p, M. H. & Dimarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 21, 201\u2013223 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"390_CR235","doi-asserted-by":"publisher","first-page":"432607","DOI":"10.1155\/2011\/432607","volume":"2011","author":"AH Sam","year":"2011","unstructured":"Sam, A. H., Salem, V. & Ghatei, M. A. Rimonabant: from RIO to ban. J. Obes. 2011, 432607 (2011).","journal-title":"J. Obes."},{"key":"390_CR236","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nut.2019.03.017","volume":"66","author":"LB Martins","year":"2019","unstructured":"Martins, L. B., Monteze, N. M., Calarge, C., Ferreira, A. V. M. & Teixeira, A. L. Pathways linking obesity to neuropsychiatric disorders. Nutrition 66, 16\u201321 (2019).","journal-title":"Nutrition"},{"key":"390_CR237","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2024. EMA https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024 (2024)."},{"key":"390_CR238","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1017\/S0033291719001454","volume":"49","author":"EF Osimo","year":"2019","unstructured":"Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B. & Khandaker, G. M. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol. Med. 49, 1958\u20131970 (2019).","journal-title":"Psychol. Med."},{"key":"390_CR239","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bbi.2023.06.023","volume":"113","author":"P Alexandros Lalousis","year":"2023","unstructured":"Alexandros Lalousis, P. et al. Inflammatory subgroups of schizophrenia and their association with brain structure: a semi-supervised machine learning examination of heterogeneity. Brain Behav. Immun. 113, 166\u2013175 (2023).","journal-title":"Brain Behav. Immun."},{"key":"390_CR240","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon, R. A., Keefe, R. S. E. & McGuire, P. K. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol. Psychiatry 28, 1902\u20131918 (2023).","journal-title":"Mol. Psychiatry"},{"key":"390_CR241","doi-asserted-by":"publisher","unstructured":"Douglas, K. M., Porter, R. J. & Young, A. H. Cognition in mood disorders. BJPsych Open https:\/\/doi.org\/10.1192\/bjo.2020.149 (2021).","DOI":"10.1192\/bjo.2020.149"},{"key":"390_CR242","unstructured":"Semaglutide for the treatment of cognitive dysfunction in major depressive disorder. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04466345 (2024)."},{"key":"390_CR243","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3, 760\u2013773 (2016).","journal-title":"Lancet Psychiatry"},{"key":"390_CR244","doi-asserted-by":"publisher","unstructured":"Abosi, O., Lopes, S., Schmitz, S. & Fiedorowicz, J. G. Cardiometabolic effects of psychotropic medications. Horm. Mol. Biol. Clin. Investig. https:\/\/doi.org\/10.1515\/hmbci-2017-0065 (2018).","DOI":"10.1515\/hmbci-2017-0065"},{"key":"390_CR245","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll, C. U., Detraux, J., De Lepeleire, J. & De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14, 119\u2013136 (2015).","journal-title":"World Psychiatry"},{"key":"390_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101962","volume":"58","author":"M Luli","year":"2023","unstructured":"Luli, M. et al. The implications of defining obesity as a disease: a report from the Association for the Study of Obesity 2021 annual conference. eClinicalMedicine 58, 101962 (2023).","journal-title":"eClinicalMedicine"},{"key":"390_CR247","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553\u20131564 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"390_CR248","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.neubiorev.2020.10.009","volume":"119","author":"E Robinson","year":"2020","unstructured":"Robinson, E., Roberts, C., Vainik, U. & Jones, A. The psychology of obesity: an umbrella review and evidence-based map of the psychological correlates of heavier body weight. Neurosci. Biobehav. Rev. 119, 468\u2013480 (2020).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"390_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109637","volume":"238","author":"G Skovbjerg","year":"2023","unstructured":"Skovbjerg, G. et al. Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging. Neuropharmacology 238, 109637 (2023).","journal-title":"Neuropharmacology"},{"key":"390_CR250","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher, A. et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473\u20134488 (2014).","journal-title":"J. Clin. Invest."},{"key":"390_CR251","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter, K. & H\u00f6lscher, C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 13, 33 (2012).","journal-title":"BMC Neurosci."},{"key":"390_CR252","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fphys.2020.00555","volume":"11","author":"Z Fu","year":"2020","unstructured":"Fu, Z. et al. Brain endothelial cells regulate glucagon-like peptide 1 entry into the brain via a receptor-mediated process. Front. Physiol. 11, 555 (2020).","journal-title":"Front. Physiol."},{"key":"390_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh, T. S., Rhea, E. M., Talbot, K. & Banks, W. A. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem. Pharmacol. 180, 114187 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"390_CR254","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","volume":"28","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A. & Holst, J. J. Glucagon-like peptide-1 and the central\/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol. Metab. 28, 88\u2013103 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"390_CR255","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/0004867418796955","volume":"52","author":"G Morris","year":"2018","unstructured":"Morris, G. et al. Leaky brain in neurological and psychiatric disorders: drivers and consequences. Aust. N. Z. J. Psychiatry 52, 924\u2013948 (2018).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"390_CR256","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1126\/science.adn4691","volume":"382","author":"J Couzin-Frankel","year":"2023","unstructured":"Couzin-Frankel, J. Obesity meets its match. Science 382, 1226\u20131227 (2023).","journal-title":"Science"},{"key":"390_CR257","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(23)01182-0","volume":"402","author":"SC Bain","year":"2023","unstructured":"Bain, S. C. & Min, T. A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena. Lancet 402, 504\u2013505 (2023).","journal-title":"Lancet"},{"key":"390_CR258","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/d41586-023-02092-9","volume":"619","author":"S Sidik","year":"2023","unstructured":"Sidik, S. Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective. Nature 619, 19 (2023).","journal-title":"Nature"}],"container-title":["Nature Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44220-025-00390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44220-025-00390-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44220-025-00390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:23:43Z","timestamp":1741681423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44220-025-00390-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":258,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1038\/s44220-025-00390-x","relation":{},"ISSN":["2731-6076"],"issn-type":[{"value":"2731-6076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.D.G., I.K., P.J.C. and C.J.H. are supported by the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (NIHR203316). M.T. and T.P. are NIHR clinical lecturers. A.I.A. is supported by the NIHR Oxford Biomedical Research Centre. I.K. declares additional funding for this work through the UK Medical Research Council (MRC) (MR\/T033371\/1), and NIHR Development and Skills Enhancement Award (NIHR301616). I.K. is also in receipt of grant funding from Novo Nordisk for an investigator-initiated study of semaglutide in Alzheimer\u2019s disease; he is paid a medical advisor for digital healthcare companies in the dementia space (Five Lives SAS, Cognetivity Ltd, Cognes Ltd). R.M. declares additional funding outside of this work by a Wellcome Trust Clinical Research Career Development Fellowship (224625\/Z\/21\/Z). P.J.C. declares additional funding for this work through the UK MRC (grant MR\/ K022202). M.S. has received honoraria or has been a consultant for Angelini, AbbVie, Boehringer Ingelheim, Lundbeck and Otsuka. R.M. has received speaker\/consultancy fees from Boehringer Ingelheim, Janssen, Karuna, Lundbeck, Otsuka and Viatris, and co-directs a company that designs digital resources to support treatment of mental ill health. T.P. has participated in educational speaker meetings for Lundbeck, Otsuka, Sunovion, Janssen, Schwabe Pharma, ROVI Biotech and Recordati; he receives book royalties from Wiley Blackwell; he co-directs a company that designs digital resources to support treatment of mental ill health. C.J.H. has received consultancy fees from P1vital, Lundbeck, Servier, UCB, Zogenix, J&J and Syndesi outside of the current work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}